ImClone Extends Deadline For Mystery Bidder
This article was originally published in The Pink Sheet Daily
Executive Summary
Name of bidder will be released whether ImClone accepts its offer or not.
You may also be interested in...
Mystery Date: ImClone Rejects Bristol For Unnamed $70 Per Share Bidder
Much industry speculation suggests Icahn seeks higher bid from BMS, which initially offered $60 per share.
Solvay's Androgel REMS Proposal May Need More Restrictions - Cmte.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee
FDA Complete Response Slows Down, But Won't Stop, Lundbeck's Serdolect
Agency comes to same conclusion as advisory committee: the risky schizophrenia drug could get approved if an appropriate patient group is identified.